Cormorant Asset Management, LP Crinetics Pharmaceuticals, Inc. Transaction History
Cormorant Asset Management, LP
- $1.43 Billion
- Q3 2024
A detailed history of Cormorant Asset Management, LP transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 1,100,000 shares of CRNX stock, worth $44.3 Million. This represents 3.94% of its overall portfolio holdings.
Number of Shares
1,100,000
Previous 1,350,000
18.52%
Holding current value
$44.3 Million
Previous $60.5 Million
7.08%
% of portfolio
3.94%
Previous 4.65%
Shares
4 transactions
Others Institutions Holding CRNX
# of Institutions
242Shares Held
80.1MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$253 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$251 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$237 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$199 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$180 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.17B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...